Breaking News

Kemwell Expands Capabilities in India

May 14, 2013

Adds analytical equipment and scientists for FTE contract

Kemwell Biopharma has expanded its analytical capabilities in India to service an FTE contract for a large, multinational pharma company. The new analytical lab is equipped with 10 HPLC's, one UPLC and nine dissolution apparatus and other analytical instruments. Kemwell will also employ 15 scientists dedicated to this project.
Ninad Deshpanday, president of R&D at Kemwell, said, "This project and lab expansion further reflects Kemwell's commitment to its customers. Kemwell has invested in a dedicated facility to meet the needs of this very important customer. The scope of the project includes method transfer, stability sample analyses and analytical method validation for various projects for the customer. We are actively looking to invest in and grow our development business."
Kemwell's R&D division employs more than 100 scientists and provides services from formulation development, analytical development and validation to clinical trial manufacturing.

Related Compliance:

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO